VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ After the investigator has taken the decision to  │ After the investigator has taken the decision to  │     100 │
│ use human insulin or insulin analogues to treat   │ use human insulin or insulin analogues to treat   │         │
│ the subject, any type 2 diabetic previously       │ the subject, any type 2 diabetic previously       │         │
│ inadequately controlled with two or more OADs is  │ inadequately controlled with two or more OADs is  │         │
│ eligible for the study                            │ eligible for the study                            │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ The selection of the subjects will be at the      │ The selection of the subjects will be at the      │     100 │
│ discretion of the individual investigator         │ discretion of the individual investigator         │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Known or suspected allergy to trial product(s) or │ Known or suspected allergy to trial product(s) or │     100 │
│ related products                                  │ related products                                  │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Subjects who are unlikely to comply with protocol │ Subjects who are unlikely to comply with protocol │     100 │
│ requirements, e.g. uncooperative attitude,        │ requirements, e.g. uncooperative attitude,        │         │
│ inability to return for the final visit           │ inability to return for the final visit           │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Subjects who previously enrolled in this study    │ Subjects who previously enrolled in this study    │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Females of childbearing potential who are         │ Females of childbearing potential who are         │     100 │
│ pregnant, breast-feeding or intend to become      │ pregnant, breast-feeding or intend to become      │         │
│ pregnant or are not using adequate contraceptive  │ pregnant or are not using adequate contraceptive  │         │
│ methods                                           │ methods                                           │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ The receipt of any investigational product within │ The receipt of any investigational product within │     100 │
│ 3 months prior to this trial                      │ 3 months prior to this trial                      │         │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Your personal trial has no unique criteria

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 100
Average Levenshtein Ratio of individual lines: 100.0
OverAll Ratio: 100.0
